Tandem Diabetes Care Expands Recall - - BioPharm International

ADVERTISEMENT

Tandem Diabetes Care Expands Recall


FDA announced that Tandem Diabetes Care (Tandem) is expanding a voluntary recall of specific lots of insulin cartridges that are used with the t:slim Insulin Pump because of a potential risk for leaking. The potential leaking could result in the device delivering too much or too little insulin, which can lead to a serious adverse event.

"The safety of our customers is our top priority. For that reason, even after our previous announcement Tandem’s team continued to perform further testing. Based on this work we recognized that additional cartridge lots could also be at risk for leaking and so we are expanding the scope of this recall," said Kim Blickenstaff, President and CEO of Tandem in a press release. "We are confident that we have identified all of the affected cartridge lots that may have been shipped to customers or distributors and that we have implemented appropriate corrective actions to prevent this from happening in the future."

Tandem has determined that under certain conditions a specific piece of equipment used in the cartridge test process caused the affected cartridges to be at risk for leaking. Tandem has already implemented modifications to the cartridge manufacturing test process to prevent this issue from occurring in the future, and the company’s manufacturing facility is able to support ongoing customer demand. The company says it is working with its customers and distributors to replace cartridges subject to the recall.

Lot recall information is available at FDA.gov.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here